Bayer
This article was originally published in The Tan Sheet
Executive Summary
Consumer Care Division sales drop of 26.6% to $385.8 mil. is "attributable to currency and portfolio trends," CEO Werner Wenning says in Aug. 5 earnings call. "Without these factors, sales were up 4.9%. Business in the U.S. was especially strong due to the nutritionals and Alka-Seltzer line. Sales were up in Mexico, Brazil and Argentina," the exec notes. August launch of Alka-Seltzer Plus Ready Release quick dissolve tablets could enhance brand's strong performance further in third quarter (1"The Tan Sheet" June 23, 2003, p. 10)...
You may also be interested in...
NACDS In Brief
Bayer: Alka-Seltzer Plus Ready Release quick dissolve tablets slated to ship in early August, firm says at National Association of Chain Drug Stores Marketplace in San Diego June 8-10. New delivery form "melts in your mouth" with "no water needed," labeling notes. Tablets in blister-pack 12-count boxes contain acetaminophen and pseudoephedrine, will be indicated for nasal congestion, runny nose, sneezing and sinus pressure. Consumers are advised to take two tablets for symptom relief; flavors include cool mint and orange zest. Bayer will support the line extension with television and print ads, as well as FSI drops in October, November and December...
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.